Aptevo Therapeutics Inc. - Common Stock, $0.001 par value per share (APVO)

Q: What does CUSIP 03835L702 represent in this 13F holders report?

CUSIP 03835L702 is the security identifier for APVO - Aptevo Therapeutics Inc. - Common Stock, $0.001 par value per share used to aggregate holder disclosures.

Q: How many institutions held APVO - Aptevo Therapeutics Inc. - Common Stock, $0.001 par value per share in Q1 2026?

2 institutional investors reported APVO - Aptevo Therapeutics Inc. - Common Stock, $0.001 par value per share for Q1 2026. Use the holders table for investor-level position and value details.

CUSIP: 03835L702

Q1 2026 13F Holders as of 31 Mar 2026

Type / Class: Equity / Common Stock, $0.001 par value per share
Shares outstanding: 1,022,610
Total 13F shares: 3,554
Share change: +3,340
Total reported value: $15,175
Price per share: $4.27
Number of holders: 2
Value change: +$14,199
Number of buys: 2
Number of sells: 1

Quarterly Holders Quick Answers

What is CUSIP 03835L702?
CUSIP 03835L702 identifies APVO - Aptevo Therapeutics Inc. - Common Stock, $0.001 par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Previous quarter: Q4 2025

Recent filing periods for CUSIP 03835L702:

Q1 2026 Q4 2025

Top shareholders of APVO - Aptevo Therapeutics Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
YA II PN, Ltd.	13D/G	—	10%	357,842	$1,663,965	$0	16 Jun 2025	13D/G
CVI Investments, Inc.	13D/G	—	8.2%	83,854	$744,624	$0	31 Dec 2025	13D/G
L1 Capital Global Opportunities Master Fund, Ltd.	13D/G	—	5%	164,300	$492,900	-$362,100	14 Aug 2025	13D/G
VANGUARD GROUP INC	13F	Company	1.6%	16,856	$158,952	—	31 Dec 2025	13F
Ayrton Capital LLC	13D/G	—	10%	358,150	$107,445	$0	30 Jun 2025	13D/G
Hudson Bay Capital Management LP	13D/G	—	5%	76,598	$52,853	$0	31 Dec 2024	13D/G
CITIGROUP INC	13F	Company	0.27%	2,756	$25,989	—	31 Dec 2025	13F
Grady Grant III	3/4/5	Director	— mixed-class rows	20,714 mixed-class rows	$20,135	+$20,134	10 Nov 2025	3/4/5
OSAIC HOLDINGS, INC.	13F	Company	0.04%	360	$3,393	—	31 Dec 2025	13F
UBS Group AG	13F	Company	0.02%	170	$1,603	—	31 Dec 2025	13F
Tower Research Capital LLC (TRC)	13F	Company	0.01%	92	$868	—	31 Dec 2025	13F
SBI Securities Co., Ltd.	13F	Company	0%	31	$292	—	31 Dec 2025	13F
BANK OF AMERICA CORP /DE/	13D/G 3/4/5 13F	10%+ Owner · Company	0%	86	$125	-$715,879	31 Oct 2025	13D/G 3/4/5 13F
Tradewinds Capital Management, LLC	13F	Company	0%	13	$118	—	31 Dec 2025	13F
FMR LLC	13F	Company	0%	7	$66	—	31 Dec 2025	13F
DANSKE BANK A/S	13F	Company	0%	1	$9	—	31 Dec 2025	13F
Marvin L. White	3/4/5	President and CEO, Director	— mixed-class rows	30,012 mixed-class rows	$3	—	06 Aug 2025	3/4/5
Jeffrey G. Lamothe	3/4/5	EVP, COO	— mixed-class rows	17,306 mixed-class rows	$1	—	06 Aug 2025	3/4/5
SoYoung Kwon	3/4/5	SVP, GC, BD & Corp Affairs	— mixed-class rows	11,504 mixed-class rows	$1	—	06 Aug 2025	3/4/5
BIGGER CAPITAL FUND L P	13D/G	—	10%	285,000	—	$0	18 Jun 2025	13D/G
Fuad El-Hibri	3/4/5	Director	— class O/S missing	87,697	—	—	03 Dec 2021	3/4/5
Daphne Taylor	3/4/5	SVP, CFO	— mixed-class rows	11,503 mixed-class rows	—	—	06 Aug 2025	3/4/5
Dirk Huebner	3/4/5	SVP, CMO	— class O/S missing	11,500	—	—	06 Aug 2025	3/4/5
Barbara Lopez Kunz	3/4/5	Director	— mixed-class rows	7,201 mixed-class rows	—	—	06 Aug 2025	3/4/5
Daniel Abdun-Nabi	3/4/5	Director	— mixed-class rows	7,201 mixed-class rows	—	—	06 Aug 2025	3/4/5
John Niederhuber	3/4/5	Director	— mixed-class rows	7,201 mixed-class rows	—	—	06 Aug 2025	3/4/5
Zsolt Harsanyi	3/4/5	Director	— mixed-class rows	7,201 mixed-class rows	—	—	06 Aug 2025	3/4/5

Institutional Holders of Aptevo Therapeutics Inc. - Common Stock, $0.001 par value per share (APVO) as of Q1 2026

As of 31 Mar 2026, Aptevo Therapeutics Inc. - Common Stock, $0.001 par value per share (APVO) was held by 2 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 3,554 shares. The largest 2 holders included UBS Group AG and SBI Securities Co., Ltd.. This page lists 2 institutional shareholders reporting positions in this security for the Q1 2026 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2026 vs Q4 2025 Across Filers

Q4 2025 holders

Q1 2026 holders

Holder diff

-8

Investor	Q4 2025 Shares	Q1 2026 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q1 2026 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.